Data-driven health employs a genome and longitudinal phenome analysis for each of many individuals to decipher their individual biological complexities and turn these insights into actionable possibilities to optimize wellness and healthy aging, to avoid disease, to identify biomarkers and candidate drug targets for wellness and prevention and to gain causal insights into wellness and disease. Information-based peptide drug discovery will employ large scale DNA synthesis to generate millions of peptide genes and then use the tools of cell and molecular biology to interrogate them individually through the windows of phenotypic and targeted selection procedures. I will discuss the application and integration of these four different paradigm changes for optimizing individual health through big data and AI, ultimately leading to an N=1 healthcare.
CEO, Phenome Health
Chief Innovation Officer,
Distinguished Professor,
Buck Institute for Research on Aging
Professor and Co-founder,
Institute for Systems Biology
CEO, Luxembourg Institute of Health
LIH Edison
Curie/Pasteur room (3rd floor)
1B rue Thomas Edison
L-1445 Strassen, Lux
Please register by sending an email to: florence.henry@lih.lu
Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.